Using Real-World Data to Improve Access for Patients

blue digital binary data on computer screen. Close-up shallow DOF

Targeting new therapeutics to the correct patient group is a challenge for pharma companies using traditional strategies. A mid-sized pharma company helped accelerate and boost the process by using real-world data (RWD). In a new sponsored article on Fierce Pharma, Carolyn Zele of MMIT and Lance Wolkenbrod discuss the issues many companies have in leveraging RWD to reach patients. One such shortcoming is insufficient data integration.

According to the authors, “Companies have been using analytics for many years but bringing together multiple data sources to inform decision-making can be a laborious process. In many pharma companies, analytics groups spend nearly 80% of their time just bridging the data together, validating and coding to develop the appropriate model, sometimes leaving only 20% of their time for the actual analytics. Developing a way to minimize this front-end burden can help you better leverage your data.”

To read more, click here.

(Source: Fierce Pharma, October 3^rd, 2022)